Patient with unresectable locally advanced non-small cell lung cancer who relapsed after chemoradiotherapy and durvalumab consolidation therapy.
Conditions
Interventions
None listed
Sponsors
Cancer and Infectious Disease Center Tokyo Metropolitan Komagome Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with NSCLC diagnosed by cytology or histology. (2) Patients with unresectable local progression or postoperative local recurrence. (3) Patients who have undergone radical CRT and at least one course of durvalumab consolidation therapy. (4) Patients who received platinum plus ICI or platinum combination therapy for recurrence from July 2, 2018 to June 30, 2023.
Exclusion criteria
Exclusion criteria: (1) Patients who had prior irradiation of all recurrent lesions. (2) Patients who were judged to be inappropriate for this study by the physician of information collection at each institution. (3) Patients with driver gene mutation (EGFR, ALK, ROS1, MET exon 14 skipping, RET, BRAF) positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) for initial chemotherapy after relapse: A survival curve will be estimated using the Kaplan-Meier method, and the median PFS and its 95% confidence interval will be calculated. To adjust for background factors, multivariate Cox regression models and propensity score matching will be used to compare groups. | — |
Countries
Japan
Contacts
Public ContactSeigo Katakura
Kanagawa Cancer Center Department of Thoracic Oncology
Outcome results
None listed